Fig. 4
From: Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
Time on treatment (months) on first-line treatment for patients in the incident study cohort (patients with the start of any major depressive disorder episode within the study period, 1/1/2016–31/5/2018), n = 2553. (Other monotherapy comprised: 39.1% venlafaxine, 21.5% duloxetine, 10.1% vortioxetine, 9.2% bupropion, 8.4% mirtazapine, 3.9% milnacipran). TCA tricyclic antidepressants, SSRI selective serotonin reuptake inhibitors